A panel of renal cell carcinoma experts deliberates on the treatment approach for a 59-year-old woman diagnosed with a left renal mass.
Videos
Rohan Garje, MD, provides an overview of a study evaluating how mutations, including TP53, RB1, and PTEN, impact overall survival in patients with metastatic prostate cancer.
Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL.
Mazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.
Timothy F. Cloughesy, MD, discusses the impact and significance of the FDA’s approval of vorasidenib, a first-in-class option for the treatment of patients with IDH-mutant gliomas.
Douglas Tremblay, MD, discusses the different cytoreduction approaches available to patients with myeloproliferative neoplasms and their safety profiles.
Yannis K. Valtis, MD, provides background on a single-institution, retrospective cohort study which assessed laboratory and clinical tumor lysis syndrome in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Paula Rodríguez Otero, MD, PhD, discussed the findings from the minimal residual disease analysis of the PERSEUS study.
Edwin Choy, MD, PhD, discusses the mechanism of action of afamitresgene autoleucel and the recent accelerated approval from the FDA for patients with advanced synovial sarcoma.
Matthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.
Pierfranco Conte, MD, discusses findings and implications of the A-BRAVE study.
The panelists examine the CheckMate-67T study, which evaluated the efficacy and safety of subcutaneous versus intravenous administration of nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma.
Mikkael Sekeres, MD details a clinical presentation of a 74-year-old man diagnosed 9 months ago with LR-MDS with a hemoglobin of 7.8 g/dL.
An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.
Mazyar Shadman, MD, MPH, discusses the safety profile of BTK inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Caitlin Costello, MD, looks to the future of treating patients with relapsed/refractory multiple myeloma, highlighting potential opportunities and challenges in the therapeutic landscape.
A hematologist-oncologist provides clinical advice to community-based clinicians on key strategies for optimizing the treatment of patients with relapsed/refractory multiple myeloma.
Caitlin Costello, MD, provides clinical insights on best practices for treating patients with relapsed/refractory multiple myeloma who receive early-line CAR T-cell therapy and later relapse.
Harry Erba, MD, PhD, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia or myelodysplastic syndrome.
An expert on relapsed/refractory multiple myeloma discusses the role of stem cell transplantation in current treatment paradigms.
Following the recent approvals of ide-cel and cilta-cel CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, a hematologist-oncologist discusses clinical research supporting their utilization.
Caitlin Costello, MD, presents the case of a 60-year-old woman with later relapsed/refractory multiple myeloma and discusses how the treatment landscape has evolved, highlighting remaining unmet needs.
Guillermo Garcia-Manero, MD, provides advice to community oncologists on the treatment of anemia for patients with lower-risk MDS.
An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.
A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.
Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.
Guillermo Garcia-Manero, MD, addresses clinical research investigating luspatercept dose titration practices in patients with lower-risk MDS.
A medical oncology specialist discusses how recent data and improvements in genomic profiling are changing the classification of lower-risk MDS.
Guillermo Garcia-Manero, MD, reviews recent results from the COMMANDS study investigating luspatercept versus epoetin alfa in patients with ESA-naïve, transfusion dependent LR-MDS.
An expert on the treatment of lower-risk MDS outlines practices for identifying patients who are suitable to receive erythroid maturating agents for treatment of anemia.